Interleukin-33 Expression on Treatment Outcomes and Prognosis in Brazilian Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
breast cancer
interleukin-33
luminal subtype
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Nov 2023
15 Nov 2023
Historique:
received:
02
10
2023
revised:
30
10
2023
accepted:
01
11
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Interleukin-33 (IL-33), a member of the interleukin-1(IL-1) family of cytokines, remains poorly understood in the context of human breast cancer and its impact on treatment outcomes. This study aimed to elucidate IL-33 expression patterns within tumor samples from a cohort of Brazilian female breast cancer patients undergoing neoadjuvant chemotherapy while exploring its correlation with clinicopathological markers. In total, 68 samples were meticulously evaluated, with IL-33 expression quantified through a quantitative polymerase chain reaction. The findings revealed a substantial upregulation of IL-33 expression in breast cancer patient samples, specifically within the Triple-negative and Luminal A and B subtypes, when compared to controls (healthy breast tissues). Notably, the Luminal B subtype displayed a marked elevation in IL-33 expression relative to the Luminal A subtype (
Identifiants
pubmed: 38003516
pii: ijms242216326
doi: 10.3390/ijms242216326
pmc: PMC10671081
pii:
doi:
Substances chimiques
Interleukin-33
0
Biomarkers, Tumor
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancers (Basel). 2021 Jun 30;13(13):
pubmed: 34209038
Oncologist. 2010;15 Suppl 5:39-48
pubmed: 21138954
Oncoimmunology. 2018 Oct 16;8(2):e1527497
pubmed: 30713780
J Int Med Res. 2012;40(5):1654-61
pubmed: 23206447
Med J Armed Forces India. 2015 Jul;71(3):254-8
pubmed: 26288493
J Pathol. 2011 Jul;224(3):389-400
pubmed: 21437909
Lung Cancer. 2015 Nov;90(2):346-51
pubmed: 26342550
Rev Med Chil. 2014 Apr;142(4):428-35
pubmed: 25117032
Cancers (Basel). 2021 Aug 25;13(17):
pubmed: 34503097
Ann Surg Oncol. 2018 Jul;25(7):1783-1785
pubmed: 29671136
World J Surg Oncol. 2018 Jan 2;16(1):1
pubmed: 29291744
J Immunol Res. 2014;2014:923135
pubmed: 24741632
Breast Cancer Res. 2014 Feb 25;16(1):204
pubmed: 25774617
Oncogene. 2007 Oct 4;26(45):6469-87
pubmed: 17471238
Dis Markers. 2016;2016:9262919
pubmed: 27340318
Rev Bras Epidemiol. 2023 May 29;26:e230028
pubmed: 37255208
Nucleic Acids Res. 2021 Jan 8;49(D1):D1074-D1082
pubmed: 33219674
World J Clin Oncol. 2014 Aug 10;5(3):382-92
pubmed: 25114853
Front Immunol. 2017 Jan 09;7:682
pubmed: 28119694
Front Med. 2021 Apr;15(2):178-207
pubmed: 33074528
Oncogene. 2015 Sep 17;34(38):4928-38
pubmed: 25531326
Oncoimmunology. 2012 Mar 1;1(2):229-231
pubmed: 22720252
South Asian J Cancer. 2021 Dec 31;10(4):220-224
pubmed: 34984199
Biochim Biophys Acta. 2011 Dec;1816(2):119-31
pubmed: 21658434
Cancer Res. 2020 Dec 1;80(23):5317-5329
pubmed: 33023944
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
J Pathol Inform. 2010 Dec 23;1:29
pubmed: 21221174
Lancet Glob Health. 2019 Jun;7(6):e784-e797
pubmed: 31097280
Mod Pathol. 2021 Jan;34(Suppl 1):94-106
pubmed: 33154551
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
J Inflamm (Lond). 2011 Aug 26;8(1):22
pubmed: 21871091
Oncotarget. 2017 May 23;8(21):35116-35123
pubmed: 28402273
Front Immunol. 2018 Dec 20;9:3051
pubmed: 30619376
Int Rev Cell Mol Biol. 2017;331:1-53
pubmed: 28325210
Int J Cancer. 2014 Apr 1;134(7):1669-82
pubmed: 24105680
Cancer Treat Rev. 2012 Oct;38(6):698-707
pubmed: 22178455
Front Immunol. 2014 Apr 07;5:141
pubmed: 24778632
Cytokine. 2022 Sep;157:155961
pubmed: 35843125
Biomed Res Int. 2014;2014:587376
pubmed: 25032216
Immunity. 2005 Nov;23(5):479-90
pubmed: 16286016